NCT06765980

A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration

A Phase 1/2, First-in-Human, Multi-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of an Adeno-associated Virus Vector VV-14295 Administered Suprachoroidally With the Everads Injector In AdultS With GeographIc Atrophy Secondary to Age-related Macular DegeneratiON (the VISION Study)

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 62 (estimated)
• Sponsor: Kriya Therapeutics, Inc. · Industry
• Sex: All
• Age: 55 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The goal of this study is to evaluate how safe and tolerable KRIYA-825 (VV-14295) is and to determine how effective it is in reducing the growth of geographic atrophy (GA) lesions in the treated eye in patients with GA secondary to age-related macular degeneration (AMD).

Conditions

• Geographic Atrophy Secondary to Age-related Macular Degeneration

Interventions

Type	Name	Description
GENETIC	VV-14295	VV-14295 will be administered as a single suprachoroidal injection.

Timeline

• Start date: 2025-05-28
• Primary completion: 2027-12-15
• Completion: 2027-12-15
• First posted: 2025-01-09
• Last updated: 2025-12-09

Locations

2 sites across 2 countries: Canada, New Zealand

Regulatory

• FDA-regulated drug study
• FDA-regulated device study